(Total Views: 324)
Posted On: 04/25/2019 10:26:18 AM
Post# of 72446
Pharma VPs and bureaucrats both make subjective decisions based on trial results. Both are risk averse.
Again, only BP can give validation of what the trial results are worth.
B-ABSSSI phase 2b was an undeniable clinical success. It remains to be seen what it is worth, if anything at all. We have yet to be able to monetize it four years later.
Again, only BP can give validation of what the trial results are worth.
B-ABSSSI phase 2b was an undeniable clinical success. It remains to be seen what it is worth, if anything at all. We have yet to be able to monetize it four years later.
(1)
(0)
